

40. Mitteilungsblatt

Nr. 58

Mitteilungsblatt der Medizinischen Universität Wien
Studienjahr 2021/2022
40. Stück; Nr. 58

Bevollmächtigungen

58. Bevollmächtigungen gem. § 27 Abs. 2 UG

58. Bevollmächtigungen gem. § 27 Abs. 2 UG

Gemäß § 27 Abs. 2 UG werden folgende Bevollmächtigungen erteilt:

Auftragsnummer	Projekttitle	Organisationseinheit	Projektleiter(in)
FA731B0212	Neoadjuvant Chemoradiotherapy with sequential Ipilimumab and Nivolumab in RECTal cancer (CHINOREC): a prospective randomized, open-label, multicenter, phase II clinical trial	Allgemeinchirurgie_731	Längle Johannes
FA731B2305	A Phase III, randomized, open-label, multicenter study, evaluating the efficacy and safety of adjuvant Giredestrant compared with physician's choice of adjuvant endocrine monotherapy in patients with estrogen receptor positive, Her2-negative early breast cancer	Allgemeinchirurgie_731	Fitzal Florian
FA731B2402	Tailored Axillary Surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS). A multicenter randomized phase III trial (TAXIS) (hereinafter referred to as "Study") on the 4th of November 2019.	Allgemeinchirurgie_731	Exner Ruth
FA738A0811	BD Spinalnadel-Anwendungsbeobachtung	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Kimberger Oliver

FA738A0812	Ärzte Ausbildung 4.0	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Kimberger Oliver
FA738A1303	Klinischen Prüfung der pharmakologische Sicherheit und Wirksamkeit des Prüfpräparates AP301 powder for reconstitution for solution for inhalation in Patienten mit pulmonalem Permeabilitätsödem bei Patienten mit mäßigem bis schwerem akutem Atemnotsyndrom (ARDS)	Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie_738	Krenn Katharina
FA613A0501	Zukunftskolleg ZK 57-B28	Anatomie und Zellbiologie_310	Vesely Cornelia
FA613A1001	Click-aktivierbare Oligonukleotide für bioorthogonale Translation	Anatomie und Zellbiologie_310	Goldeck Marion
FA746A0269	A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE- MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (LUCERNE)	Augenheilkunde und Optometrie_746	Schmidt- Erfurth Ursula
FA746A0270	A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE- MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (TENAYA)	Augenheilkunde und Optometrie_746	Schmidt- Erfurth Ursula

FA746A0273	A Phase 2, Prospective, Randomized, Double-Masked, Active-Comparator Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Repeated Intravitreal Administration of KSI-301 in Subjects with Neovascular (Wet) Age-Related Macular Degeneration	Augenheilkunde und Optometrie_746	Schmidt-Erfurth Ursula
FA746A0275	A one-year, single-arm, open-label, multicenter study assessing the anatomic outcomes of brolocizumab assessed by OCT-A in adult patients with neovascular age related macular degeneration	Augenheilkunde und Optometrie_746	Schmidt-Erfurth Ursula
FA746A0418	Multicentric evaluation of best corrected visual acuity of the XEN implant versus classic trabeculectomy in open angle glaucoma subjects	Augenheilkunde und Optometrie_746	Vass Clemens
FA746A1632	A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement	Augenheilkunde und Optometrie_746	Sacu Gülhan Stefan
FA746A1632	A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement	Augenheilkunde und Optometrie_746	Sacu Gülhan Stefan

FA746A1643	A multicenter, open-label extension study to evaluate the long-term safety and tolerability of the port delivery system with ranibizumab in patients with neovascular age-related macular degeneration	Augenheilkunde und Optometrie_746	Sacu Gülhan Stefan
FA746A1644	A phase IIIb, multicenter, randomized, visual assessor-masked study of the effectiveness and safety of a 36-week refill regimen for the port delivery system with ranibizumab vs aflibercept treat & extend in subjects with neovascular age-related macular degeneration	Augenheilkunde und Optometrie_746	Sacu Gülhan Stefan
FA746A2608	A phase III multicenter, randomized, double-blind, double-dummy study to evaluate safety and efficacy of ocrelizumab in comparison with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis	Augenheilkunde und Optometrie_746	Pemp Berthold
FA746A2805	A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer	Augenheilkunde und Optometrie_746	Dunavölgyi Roman
FA746A3107	General Research Funding - Funding Agreement	Augenheilkunde und Optometrie_746	Leydolt Christina
FA746A3108	Data Transfer - Rotational stability of hydrophobic acrylic intraocular lenses	Augenheilkunde und Optometrie_746	Leydolt Christina
FA746A3403	AI-based analysis DERBY & OAKS studies	Augenheilkunde und Optometrie_746	Bogunovic Hrvoje

FA746A3602	Research Collaboration Agreement between RetInSight GmbH - Medical University of Vienna regarding phd studies	Augenheilkunde und Optometrie_746	Reiter Gregor Sebastian
FA746A3701	Rotational stability and refractive outcomes of the single piece hydrophobic acrylic Clareon toric intraocular lens - IIT#69799777	Augenheilkunde und Optometrie_746	Schartmüller Daniel
FA746A3801	PRA/JANSSEN Retrospektive Studie zur Dokumentation und Beschreibung der krankheitsbezogenen klinischen, individuellen und soziodemografischen Merkmale von Patienten mit X-chromosomaler Retinitis pigmentosa (XLRP) und der Auswirkungen von XLRP auf Patienten und deren Betreuungspersonen durch Überprüfung von Krankenakten in Kombination mit Querschnittsbefragungen von Patienten und Betreuungspersonen	Augenheilkunde und Optometrie_746	Ritter Markus
FA662A0314	"Safety and Efficiency of Herpes Vaccines"	Biomedizinische Forschung_308	Bergmeister Helga
FA662A0404	Pharmakokinetic study of Ratercept (ACE-031) in male/female rats after single dose administration	Biomedizinische Forschung_308	Podesser Bruno Karl
FA662A0405	Explorative Studie in Ratten	Biomedizinische Forschung_308	Podesser Bruno Karl
FA662A0406	Octapharma AG - Appendix A	Biomedizinische Forschung_308	Podesser Bruno Karl
FA662A0701	Osteokonduktive, anti-mikrobielle Beschichtungen für komplikationsfreie Polymer-3D-gedruckte Gesichts-Implantate	Biomedizinische Forschung_308	Kapeller Barbara

FA662A0801	Funktionelle Regeneration von Meniskus mithilfe von 3D-Druck mit "Bioinks" basierend auf Seide-Menisc 3D-Seidendruck	Biomedizinische Forschung_308	Schneider Karl
FA727A0901	A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia	Blutgruppenserologie und Transfusionsmedizin_727	Körmöczi Günther
FA696A0201	Biomarker signatures of diet, physical activity and sleep in children and youth	Core Facilities_2012	Kratochwill Klaus
FA654A0301	Oberfläche&Rheologie	Core Facility Labortierzucht und -haltung_668	Windberger Ursula
FA722A0203	Immunostaining of a phase 1 study to assess the safety, pharmacokinetics, and pharmacodynamics of ADX-097	Dermatologie_722	Stary Georg
FA722A1801	A European prospective study on serum antibodies against target antigens of bullous autoimmune diseases and genetic susceptibility	Dermatologie_722	Bauer Wolfgang
FA722B1113	BRF115532, COMBI-AD: A Phase III randomized double blind study of dabrafenid (GSK2118436) in COMBination with trametinib (GSK1120212) versus two placebos in the ADjuvant treatment of high-risk BRAF V600 mutation-positive melanoma after srgical resection	Dermatologie_722	Höller Christoph
FA722B1707	Wirksamkeit und Sicherheit von Dimethylfumarat bei Patienten mit Palmoplantarer Pustulose - eine offene Phase II Studie über 24 Wochen.	Dermatologie_722	Radakovic Sonja

FA722B2101	A Multicentre International Observational Prospective Study For The Identification Of Prognostic Factors In Patients With Mycosis Fungoides/Sezary Syndrome: Proposal For An International Prognostic Index For Cutaneous Lymphoma.	Dermatologie_722	Jonak Constanze
FA722B2201	A multicentre, double blind, randomised, placebo-controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy – the RESMAIN Study	Dermatologie_722	Jonak Constanze
FA722B2203	Psoriasis therapie-Register Graz	Dermatologie_722	Jonak Constanze
FA722B2308	Hypertrophe Narben	Dermatologie_722	Mildner Michael
FA722C0435	A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection”	Dermatologie_722	Rieger Armin
FA722C1205	A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to evaluate the efficacy and safety of two dose levels of BCX7353 as an oral treatment for the prevention of attacks in subjects with Hereditary Angioedema.	Dermatologie_722	Kinaciyani Tamar

FA722C1211	Retrospektive Beobachtungsstudie mit Überprüfung der Krankenakten zur Beurteilung der klinischen Wirksamkeit und des Krankheits-/Therapiemanagements bei Patienten, die mit dem Erhalt der Langzeitprophylaxe Takhzyro® im realen Umfeld begonnen haben	Dermatologie_722	Kinaciyan Tamar
FA722C1408	A multi-center, randomized, double-blind, active and placebo-controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic Spontaneous Urticaria (CSU) in adolescents and adults inadequately controlled with H1-antihistamines.	Dermatologie_722	Bangert Christine
FA722C1415	A randomized, double-blinded, active comparator-controlled, 16-week, single-site, exploratory, mechanistic trial to assess the effect of LEO 138559 on the molecular signature and safety in adults with moderate to severe atopic dermatitis	Dermatologie_722	Bangert Christine
FA722C1601	"Deciphering genomic aberrations in rare skin cancers to find mechanism-based treatment strategies"	Dermatologie_722	Wiesner Thomas
FA603A0301	Hirnforschung an Instituten der Kaiser-Wilhelm-Gesellschaft im Kontext nationalsozialistischer Unrechtstaten: Hirnpräparate in Instituten der Max-Planck-Gesellschaft und die Identifizierung der Opfer	Ethik, Sammlungen und Geschichte der Medizin_390	Czech Herwig

FA751C0136	MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer: a randomized double-blinded placebo-controlled multi-centre phase III Trial including LOGOS	Frauenheilkunde_751	Reinhaller Alexander
FA751C0518	A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 26 weeks in postmenopausal women	Frauenheilkunde_751	Wenzl René
FA751C0518	A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 26 weeks in postmenopausal women	Frauenheilkunde_751	Wenzl René
FA751C0622	A randomized, multicenter, open label phase III study to evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy for patients with HER2-positive primary breast cancer who have residual tumor present pathologically in the breast or axillary lymph nodes following preoperative therapy	Frauenheilkunde_751	Singer Christian
FA751C0646	A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer	Frauenheilkunde_751	Singer Christian

FA751C0654	A prospective, open, randomized, phase II study of carboplatin/ olaparib in the pre-operative treatment of patients with triple-negative primary breast cancer which exhibit the features of positive homologous recombination deficiency (HRD) status	Frauenheilkunde_751	Singer Christian
FA751C0675	Tailored Axillary Surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer. A multicenter randomized phase III trial	Frauenheilkunde_751	Singer Christian
FA751C0676	Alpelisib (Piqray®) Post-Authorization Safety Study (PASS): a non-interventional study of alpelisib in combination with fulvestrant in postmenopausal women, and men, with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), locally advanced or metastatic breast cancer with a phosphatidylinositol-3-kinase catalytic subunit alpha (PIK3CA) mutation, in the real-world setting	Frauenheilkunde_751	Singer Christian
FA751C1205	Video-assisted genetic counselling for hereditary breast and ovarian cancer	Frauenheilkunde_751	Pfeiler Georg
FA751C1501	Improvement of taste perception by homoeriodictyol in cancer patients after chemotherapy	Frauenheilkunde_751	Grimm Christoph
FA751C1604	A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second or Third Line Recurrent or Metastatic Cervical Cancer	Frauenheilkunde_751	Polterauer Stephan

FA751C1801	Die Effekte von Präbiotika bei Patientinnen mit Ovarialkarzinom unter Chemotherapie - Pilotstudie	Frauenheilkunde_751	Aust Stefanie
FA751C1901	Treatment regimens and outcomes of BC patients with BRCA gene variants - a study of the ATHENA registry	Frauenheilkunde_751	Tan Yen Yen
FA751D1204	A double-blind, randomized, placebocontrolled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 26 weeks in postmenopausal women.	Frauenheilkunde_751	Ott Johannes
FA751D1204	A double-blind, randomized, placebocontrolled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 26 weeks in postmenopausal women.	Frauenheilkunde_751	Ott Johannes
FA751D1401	Messung der Körperkerntemperatur zur Bestimmung der fertilen Tage bei Frauen mit polyzystischem Ovarsyndrom - eine prospektive Kohorten-Pilotstudie	Frauenheilkunde_751	Hager Marlene
FA751D1501	Challenges of human reproductive medicine in a changing Europe: an innovative professional curriculum for graduate medical education	Frauenheilkunde_751	Rosta Klara
CD10274401	Christian Doppler Laboratory for Inner Ear Research: Function Preservation and Regeneration	Hals-, Nasen- und Ohrenkrankheiten_744	Arnoldner Christoph
FA744A0202	Effects of locally applied glucocorticoids and selective glucocorticoid receptor agonists on the inner ear in an animal model	Hals-, Nasen- und Ohrenkrankheiten_744	Arnoldner Christoph

FA744B0803	Frequency compression in SAMBA 2 users	Hals-, Nasen- und Ohrenkrankheiten_744	Riss Dominik
FA744B1403	Evaluierung der Roboter-gestützten Cochlea Implantation (HEARO) an Leichenpräparaten - Nachfolgeprojekt	Hals-, Nasen- und Ohrenkrankheiten_744	Gstöttner Wolfgang
FA744C0105	APrevent Vocal Implant System (VOIS) zur anpassbaren Behandlung der einseitigen Stimmbandlähmung (UVFP) - eine offene, nicht randomisierte Pilotstudie	Hals-, Nasen- und Ohrenkrankheiten_744	Schneider-Stickler Berit
FA731C1409	Educational Grant: Advanced training in surgical therapy of congenital heart valve defects	Herzchirurgie_732	Wiedemann Dominik
FA731C1803	Randomized comparison of the clinical Outcome of single versus Multiple Arterial grafts: the ROMA trial	Herzchirurgie_732	Sandner Sigrid
FA731C2102	Intuity Database	Herzchirurgie_732	Andreas Martin
FA731C2107	The TransCatheter Valve and Vessels Trial (TCW Trial) - A Prospective Randomized Controlled International Multicenter Clinical Trial	Herzchirurgie_732	Andreas Martin
FA732A0303	Prediction of Interventional Mitral Valve Procedural Outcome	Herzchirurgie_732	Andreas Martin
FA732A0404	Ausbildungsvertrag - VAD Coordinator Course / HeartMate 3TM LVAS Training	Herzchirurgie_732	Schlöglhofer Thomas
FA732A0501	Feasibility study of a novel cavopulmonary assist device	Herzchirurgie_732	Granegger Marcus
FA732A0503	Optimized Hydrodynamic Flow Behaviour by Selective Surface Structured of Ceramic 3D Printed Rotodynamic Blood Pumps.	Herzchirurgie_732	Granegger Marcus
FA732A0504	Interaktion zwischen einer neuartigen Blutpumpe und dem kardiovaskulären System	Herzchirurgie_732	Granegger Marcus

FA732A0601	Medtronic SYMBIOSIS Post-Market Registry	Herzchirurgie_732	Wiedemann Dominik
FA732A0602	Kurzfristige Kreislaufunterstützung mit VA-ECMO (Veno-Arterielle Extrakorporale membranoxxygenierung) unter Verwendung der Eurosets ECMOLIFE Konsole an der Medizinischen Universität Wien	Herzchirurgie_732	Wiedemann Dominik
FA732A0701	Effects of CytoSorb® haemoadsorption in heart transplantation	Herzchirurgie_732	Zuckermann Andreas
FA633A0201	Neuronal and Neuropeptidergic Mechanisms for Flexible Control of Learning and Memory	Hirnforschung_360	Melzer Sarah
FA633A0202	Neuropeptidergic modulation of synaptic circuits in fear and anxiety	Hirnforschung_360	Melzer Sarah
FA711A0163	A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) Glioblastoma	Innere Medizin I_711	Preusser Matthias
FA711A0410	Quads	Innere Medizin I_711	Knapp Sylvia
FA711A0501	Mathematical Modelling for Microbial Community Induced Metabolic Diseases	Innere Medizin I_711	Widder Stefanie
FA711B0506	A randomized, multicenter, open label phase III study to evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy for patients with HER2-positive primary breast cancer who have residual tumor present pathologically in the breast or axillary lymph nodes following preoperative therapy	Innere Medizin I_711	Preusser Matthias

FA711B0566	A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in BRCA mutated high risk HER2-negative breast cancer patients who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy (OLYMPIA)	Innere Medizin I_711	Preusser Matthias
FA711B0572	A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy	Innere Medizin I_711	Preusser Matthias
FA711B0584	A phase I/II study of ¹⁷⁷ Lu-HH1 (Betalutin™) radioimmunotherapy for treatment of relapsed CD37+ non-Hodgkin lymphoma	Innere Medizin I_711	Preusser Matthias
FA711B0592	Personalized marker-driven early switch to aflibercept on patients with metastatic colorectal cancer (PERMAD-Trial)	Innere Medizin I_711	Preusser Matthias
FA711B0712	Randomisierte Phase II, 2-Arm Studie bei für Transplantation ungeeignete Patienten mit neu diagnostizierten multiplen Myelom (NDMM) zum Vergleich von Carfilzomib + Thalidomid + Dexamethason (KTD) Induktionstherapie mit Carfilzomib + Lenalidomid + Dexamethason (KRD) Induktionstherapie in Bezug auf Ansprechraten und Untersuchung einer Monotherapie mit Carfilzomib (K) als Erhaltungstherapie (AGMT_M	Innere Medizin I_711	Valent Peter

FA711B0726	A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer	Innere Medizin I_711	Preusser Matthias
FA711B0810	A prospective, open, randomized, phase II study of carboplatin/ olaparib in the pre-operative treatment of patients with triple-negative primary breast cancer which exhibit the features of positive homologous recombination deficiency (HRD) status	Innere Medizin I_711	Preusser Matthias
FA711B0904	A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma	Innere Medizin I_711	Preusser Matthias
FA711B0981	A Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)	Innere Medizin I_711	Preusser Matthias

FA711B0991	A Randomised, Double-Blind, Phase III Study of AZD9833 plus Palbociclib versus Anastrozole plus Palbociclib in Patients with ER-Positive HER2-Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease	Innere Medizin I_711	Preusser Matthias
FA711B0992	Offene, randomisierte, kontrollierte globale Studie der Phase III mit Telisotuzumab-Vedotin (ABBV 399) im Vergleich zu Docetaxel bei Patienten mit vorbehandeltem, c-Met-überexprimiertem und lokal fortgeschrittenem/metastasierendem Nicht-Plattenepithel-, nicht kleinzelligem Lungenkarzinom (NSCLC) mit EGFR-Wildtyp	Innere Medizin I_711	Preusser Matthias
FA711B0993	Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy - The Phase II/III RAMIRIS STUDY	Innere Medizin I_711	Preusser Matthias
FA711B0994	Forschungsförderung FORUM Krebs bei Frauen	Innere Medizin I_711	Preusser Matthias
FA711C0906	A Randomized, Open-Label, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of Paroxysmal Nocturnal Hemoglobinuria in Subjects with Inadequate Response to C5 Inhibitor Therapy	Innere Medizin I_711	Valent Peter
FA711C0907	Austrian Interdisciplinary Amyloidosis Registry	Innere Medizin I_711	Valent Peter

FA711C0908	Extended Access of Mometotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)	Innere Medizin I_711	Valent Peter
FA711C0909	Isatuximab in combination with Lenalidomide-Dexamethasone compared to Lenalidomide-Dexamethasone in elderly patients (aged ≥ 70 years) with newly diagnosed myeloma: a randomized phase II study (SGZ-2019-12650) (AGMT_MM-4)	Innere Medizin I_711	Valent Peter
FA711C0910	Analysis of serologic and molecular markers and their relation to therapy to optimize personalized medicine strategies in AML: A Registry Study	Innere Medizin I_711	Valent Peter
FA711C0911	A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic	Innere Medizin I_711	Valent Peter
FA711C0912	Wirksamkeit und Sicherheit von BLENREP bei Multiplem Myelom (BEaMM) - Nachweise aus der Praxis bei Patienten, die Belantamab Mafodotin in Europa anwenden	Innere Medizin I_711	Valent Peter
FA711C0913	An open-label, single-arm multicentre Phase 1b study to evaluate the safety, efficacy and pharmacokinetics of multiple doses of ELA026 in adults and adolescents with sHLH	Innere Medizin I_711	Valent Peter

FA711C1035	A phase 2, open-label, monotherapy, multicenter study to evaluate the efficacy and safety of INCB54828 in subjects with myeloid/lymphoid neoplasms with FGFR1 rearrangement	Innere Medizin I_711	Valent Peter
FA711C1042	A prospective, non-interventional biomedical research study of genetic aberrations and immunity in myeloproliferative neoplasms	Innere Medizin I_711	Valent Peter
FA711C1079	ESMART: Supporting Myeloma Patients using the Advanced Symptom Management System (ASYMS) Remote Technology	Innere Medizin I_711	Valent Peter
FA711C1084	Supporting CLL Patients using the Advanced Symptom Management System (ASYMS) Remote Technolog	Innere Medizin I_711	Valent Peter
FA711C1097	eSMART: Verlaufsuntersuchung von Lebensqualität bei Krebspatienten der Abteilung für Hämatologie mittels der psychoonkologischen Basisdiagnostik	Innere Medizin I_711	Valent Peter
FA711C1402	Patient-reported Quality of Life in Haemophilia in Real-World Practice	Innere Medizin I_711	Ay Cihan
FA711D0501	Establishing Galleria Mellonella culture for discovering plant-based anti-infective drugs	Innere Medizin I_711	Lell Bertrand
UE71106004	Personalkostenförderung	Innere Medizin I_711	Valent Peter
UE71106013	Spende der Amgen GmbH – Personalkostenförderung	Innere Medizin I_711	Pabinger Ingrid
UE71106016	Personalkostenförderung Data Manager	Innere Medizin I_711	Valent Peter
FA714B0387	Eine multizentrische, randomisierte, doppelblinde, placebokontrollierte Dosisfindungsstudie der Phase IIb zu Rodatristat-Ethyl bei Patienten mit pulmonal-arterieller Hypertonie	Innere Medizin II_714	Lang Irene

FA714B0388	“Global SYMPLICITY Registry (GSR) Denervation Findings in Real World (DEFINE) is referred to as the GSR DEFINE Study	Innere Medizin II_714	Lang Irene
FA714B0529	EU H2020 731532 - ReGenHeart	Innere Medizin II_714	Pavone-Gyöngyösi Mariann
FA714B0538	Animal study protocol Hbtological and pharmacoknotlc assessment of use of new drug-coated balloon in rabbit iliac arteries	Innere Medizin II_714	Pavone-Gyöngyösi Mariann
FA714B1509	DYNAMIC - Evaluation of the pharmacodynamic effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction in a randomized, double blind, placebo controlled, parallel group, multicenter study	Innere Medizin II_714	Kastner Johannes
FA714B1525	HFpEF Register "Predictors of outcome in heart failure with normal ejection fraction"	Innere Medizin II_714	Kastner Johannes
FA714B2014	Cardiovascular and Renal Treatment in Heart Failure Patients with Hyperkalaemia or at High Risk of Hyperkalaemia	Innere Medizin II_714	Hülsmann Martin
FA714B2304	A retrospective-prospective observational study to assess Landiolol utilization patterns in patients with supraventricular tachycardia, for rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter, for short-term control of the ventricular rate, or for non-compensatory sinus tachycardia.	Innere Medizin II_714	Siller-Matula Jolanta
FA714B2905	Herzamyloidose bei TAVI	Innere Medizin II_714	Nitsche Christian

FA714B3110	A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amyloidosis	Innere Medizin II_714	Kastner Johannes
FA714B3111	A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis	Innere Medizin II_714	Kastner Johannes
FA714B4208	Spiroergometrie Register zur Evaluierung von prognostischen Faktoren bei Herzerkrankungen – ein monozentrisches, retrospektives und prospektives Register	Innere Medizin II_714	Badr Eslam Roza
FA714B4304	A Multicenter, Cross-sectional study to Characterize the Distribution of Lipoprotein(a) Levels Among Patients with Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)	Innere Medizin II_714	Speidl Walter
FA714B4702	Einfluss der Diabetes-Medikation auf den Krankheitsverlauf in Patienten mit Herzinsuffizienz vom HFpEF-Typ	Innere Medizin II_714	Badr Eslam Roza
FA714B4906	A phase 2b, open-label, efficacy and safety study of ABX464 as maintenance therapy in patients with moderate to severe Ulcerative Colitis	Innere Medizin II_714	Kastl Stefan

FA714B4907	A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy	Innere Medizin II_714	Kastl Stefan
FA714B4908	Randomisierte, doppelblinde, placebokontrollierte klinische Phase-III-Studie zur Bewertung der Sicherheit und Wirksamkeit einer adjuvanten Therapie mit Atezolizumab oder Placebo und Trastuzumab-Emtansin bei Her2-positiven Mammakarzinomen mit hohem Rezidivrisiko nach präoperativer Therapie	Innere Medizin II_714	Kastl Stefan
FA714B5302	Unveiling Cardiac Amyloidosis and its Characteristics among Patients with Severe Mitral Regurgitation undergoing Transcatheter Edge-to-Edge Mitral Valve Repair	Innere Medizin II_714	Nitsche Christian
FA714B5501	FREELINE FLT190-01_1011569	Innere Medizin II_714	Gatterer Constantin
FA714B5601	A Phase 3, Multinational, Randomized, Placebo-controlled Study of ARRY-371797 (PF-07265803) in Patients with Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation (REALM-DCM)" ("Study")	Innere Medizin II_714	Pavo Noemi

FA714C0315	Eine multizentrische Querschnittsstudie zur Charakterisierung der Verteilung der Lipoprotein(a)-Spiegel bei Patienten mit nachgewiesener atherosklerotischer Herz-Kreislauf-Erkrankung (ASCVD) in der Vorgeschichte (Protokoll 20210057) - CTA Amgen 20210057 pre-screening Studie für AMG 890 20180244 (CVOT)	Innere Medizin II_714	Schernthaler Gerit
FA714C0803	A retrospective Post Market Clinical Follow-up (PMCF) study evaluating the safety and clinical performance of the SABER OTW PTA Dilatation Catheter, SABERX PTA Dilatation Catheter, and Powerflex Pro PTA Catheter used in infra-popliteal vessels, during Percutaneous Transluminal Angioplasty (PTA) Procedures	Innere Medizin II_714	Gschwandtner Michael
FA714D0702	A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS	Innere Medizin II_714	Gysan Maximilian
FA716B1002	Eine randomisierte, doppelblinde, Placebo kontrollierte Studie zur Bewertung der Sicherheit und Wirksamkeit von Crinercerfont (NBI-74788) bei erwachsenen Patienten mit klassischem kongenitalem adrenogenitalem Syndrom, gefolgt von einer unverblindeten Behandlung	Innere Medizin III_716	Kiefer Florian
FA716B1310	Evaluation of long-term complications after bariatric surgery - A questionnaire-based long-term follow-up pilot study	Innere Medizin III_716	Krebs Michael
FA716B1405	Thiazide treatment in permanent hypoparathyroidism	Innere Medizin III_716	Vila Greisa

FA716C0828	A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis	Innere Medizin III_716	Sunder-Plaßmann Gere
FA716C1022	"A controlled, open-label, post authorisation efficacy and safety study in Imlifidase desensitized kidney transplant patients with positive crossmatch against a deceased donor prior to Imlifidase treatment, including non-comparative registry and concurrent reference cohorts"	Innere Medizin III_716	Oberbauer Rainer
FA716C2801	A very low carbohydrate ketogenic diet for Ip(a) lowering - an exploratory case study	Innere Medizin III_716	Kovarik Johannes
FA716D0720	„A TWINSS extension trial to evaluate the safety and tolerability of CFZ533 (iscalimab) at two dose levels administered subcutaneously in patients with Sjögren’s Syndrome“	Innere Medizin III_716	Scheinecker Clemens
FA716D0811	“Susceptibility for Transition of Progression to Psoriatic Arthritis (STOP-PsA) trial”	Innere Medizin III_716	Aletaha Daniel

FA716D1302	Targeting the type I interferon (IFN) receptor in rheumatoid arthritis (RA) patients with a high IFN signature – A multicenter, randomised, double-blind, placebo-controlled Phase 2A/ proof-of-concept study to evaluate the efficacy and safety of an intravenous treatment regimen of 300 mg Anifrolumab versus placebo in patients with moderately to severely active RA who did not respond to biological disease-modifying anti-rheumatic drugs (bDMARDs) and who have a high IFN-signature	Innere Medizin III_716	Smolen Josef
FA716D2101	BGP in osteoarthritis	Innere Medizin III_716	Mandl Peter
FA716E0840	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib	Innere Medizin III_716	Trauner Michael
FA716E0844	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB AS AN INDUCTION AND MAINTENANCE TREATMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE	Innere Medizin III_716	Trauner Michael
FA716E0855	A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis	Innere Medizin III_716	Trauner Michael

FA716E0943	Effects of Plasma Exchange with Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects with "Acute-On-Chronic Liver Failure" (ACLF) at High Risk of Hospital Mortality	Innere Medizin III_716	Trauner Michael
FA716E0949	Consultancy Agreement Boehringer Ingelheim International GmbH	Innere Medizin III_716	Trauner Michael
FA716E1008	A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis	Innere Medizin III_716	Trauner Michael
FA716E1009	A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial hemoembolization (TACE) in intermediate-stage HepatoCellular Carcinoma	Innere Medizin III_716	Trauner Michael
FA716E1010	Eine multizentrische, doppelblinde, randomisierte, placebokontrollierte Studie der Phase IIa zur Bewertung der Wirksamkeit von Spesolimab (BI 655130) bei Patienten mit fibrostenotischem Morbus Crohn	Innere Medizin III_716	Trauner Michael
FA716E1011	Randomised, double-blind, placebo-controlled and parallel group trial to investigate the effects of two doses (up-titration to a fixed dose regimen) of oral BI 685509 on portal hypertension after 24 weeks treatment in patients with clinically significant portal hypertension (CSPH) in compensated cirrhosis	Innere Medizin III_716	Trauner Michael

FA716E1012	A phase IIb, double-blind, randomised, placebo-controlled, trial to evaluate the efficacy and tolerability of ZED1227 in celiac disease subjects experiencing symptoms despite gluten-free diet	Innere Medizin III_716	Trauner Michael
FA716E1013	A follow-up Phase II open-label study to evaluate the long-term safety and efficacy profile of ABX464 given at 25 mg once daily in subjects with Moderate to Severe Active Ulcerative Colitis"	Innere Medizin III_716	Trauner Michael
FA716E1014	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Crohn's Disease (CD): AIM-CD	Innere Medizin III_716	Trauner Michael
FA716E1015	Advanced characterization of the Austrian HDV cohort	Innere Medizin III_716	Trauner Michael
FA716E1016	A Randomised Double-Blind Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Cobitolimod as an Induction and Maintenance Therapy in Participants with Moderate to Severe Active Left-Sided Ulcerative Colitis	Innere Medizin III_716	Trauner Michael
FA716E1017	ProSPective ObservaTionaL Study on the Clinical Outcomes of Surgical InTErventions in Complex Fistulizing Conditions (CPF-CD, CD-RVF, CCF)	Innere Medizin III_716	Trauner Michael
FA716E1018	An open label randomised phase 2 study to evaluate the safety and efficacy of MTL-CEBPA administered in combination with sorafenib or sorafenib alone in TK1 naive participants with previously treated advanced hepatocellular carcinoma (HCC) and hepatitis B or hepatitis C virus (Outreach2)	Innere Medizin III_716	Trauner Michael

FA716E1019	Randomisierte, unverblindete klinische Studie mit Parallelgruppen zur Untersuchung der Wirkungen von oralem BI 685509 als Monotherapie oder in Kombination Empagliflozin auf portale Hypertension nach 8 Behandlungswochen bei Patienten mit klinisch signifikanter portaler Hyperetnsion (CSPH) bei kompensierter Zirrhose	Innere Medizin III_716	Trauner Michael
FA716F0106	Optimal gender-specific treatment paths on healthcare multiplex networks	Innere Medizin III_716	Kautzky-Willer Alexandra
FA716F0109	A prospective randomized controlled pilot study to investigate the effect of intramuscular testosterone supplementation vs placebo on intrahepatic fat content in obese men with uncontrolled type 2 diabetes (T2DM) suffering from hypogonadism.	Innere Medizin III_716	Kautzky-Willer Alexandra
FA781B1204	A prospective, multicenter, double blind, placebo-controlled, two-arm parallel group phase 3 trial to evaluate the effect of early postnatal additional high dose oral vitamin A supplementation of 5000 IU/kg/d versus placebo for 28 days for preventing bronchopulmonary dysplasia (BPD) or death in extremely-low-birth-weight (ELBW) infants (Neo VitaA)	Kinder- und Jugendheilkunde_781	Binder Christoph
FA781B2201	Mein Logbuch - Ich kenne mich aus!	Kinder- und Jugendheilkunde_781	Weiler-Wichtl Liesa
FA781B2202	Neuropsychology for you! Ein Programm zur Implementierung neuropsychologischer Diagnostik, Befundbesprechungen und Behandlung in die Versorgung	Kinder- und Jugendheilkunde_781	Weiler-Wichtl Liesa

	der pädiatrischen Neuroonkologie		
FA781B2205	Junior Research Academy	Kinder- und Jugendheilkunde_781	Weiler-Wichtl Liesa
FA781B2603	Effects of an exclusive human-milk diet in preterm NEOnates on early VAScular aging risk factors (NEOVASC)	Kinder- und Jugendheilkunde_781	Binder Christoph
FA781B2604	Prophylactic treatment of the ductus arteriosus in preterm infants by acetaminophen	Kinder- und Jugendheilkunde_781	Binder Christoph
FA781B2708	TARGET study – Tidal volume Assessment in Real- time for potential tarGeted rEspiratory Treatment in neonates	Kinder- und Jugendheilkunde_781	Wagner Michael
FA781B3101	Untersuchung des Einflusses des EGF-Rezeptors auf das Wachstum von Subependymalen Riesenzellastrozytomen	Kinder- und Jugendheilkunde_781	Scholl Theresa
FA781B3202	A Phase 1/2, Multicenter, Open-label, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in Pediatric Patients with Relapsed/Refractory Solid Tumors Harboring a Mutation in KIT or PDGFRA	Kinder- und Jugendheilkunde_781	Gojo Johannes Salomon
FA781B3503	EPILEPSY-RARE Vienna - Seltene EPILEPSIen bei Kindern und Jugendlichen – Prospektives Register zur Beschreibung des Verlaufs, der Anfallslast und des Outcomes kindlicheR Epilepsiesyndrome an der Medizinischen Universität Wien.	Kinder- und Jugendheilkunde_781	Male-Dressler Anastasia
FA781F1006	FH-Register - Familiäre Hypercholesterinämie	Kinder- und Jugendheilkunde_781	Greber-Platzer Susanne

FA781F1203	A Randomized, Double blind, Placebo controlled, Ascending Multiple dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Romosozumab in Children and Adolescents with Osteogenesis Imperfecta	Kinder- und Jugendheilkunde_781	Raimann Adalbert
FA781F1702	A phase III multicenter, randomized, double-blind, double-dummy study to evaluate safety and efficacy, of Ocrelizumab in comparison with Fingolimod in children and adolescents with relapsing-remitting multiple sclerosis	Kinder- und Jugendheilkunde_781	Breu Markus
FA781F1801	Open-label Uncontrolled Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod in Children From 2 to Less Than 18 Years of Age with Generalized Myasthenia Gravis	Kinder- und Jugendheilkunde_781	Freilinger Michael
FA781G0112	IMPROVE – PD: Identification and Management of Patients at Risk – Outcome and Vascular Events in Peritoneal Dialysis	Kinder- und Jugendheilkunde_781	Aufricht Christoph
FA781G0113	Secondary Analysis of data of the phase II trial to evaluate efficacy of PD-protect® in peritoneal dialysis in patients with chronic renal failure – MAPE3	Kinder- und Jugendheilkunde_781	Aufricht Christoph
FA781G0301	Development of Transition Programme for adolescent patients with juvenile idiopathic arthritis	Kinder- und Jugendheilkunde_781	Ulbrich Andrea
FA781G0303	Valentina and the waterslide - a childrens book for psychoeducation before kidney transplant in children with chronic kidney disease	Kinder- und Jugendheilkunde_781	Ulbrich Andrea

FA781G0601	A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age-and body weight-adjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children, 6 months to <18 years of age, with chronic kidney disease and proteinuria	Kinder- und Jugendheilkunde_781	Heindl-Rusai Krisztina
FA781G0701	AustRIan RESistant NEPHROtic Syndrome Treatment Response RegIStry (ARREST-NEPHROSIS)	Kinder- und Jugendheilkunde_781	Böhm Michael
UE78106015	NF Forscherwerkstatt	Kinder- und Jugendheilkunde_781	Pletschko Thomas
FA729A0164	Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ELA026 Following Intravenous and/or Subcutaneous Administration of Single and Multiple Doses in Healthy Adults	Klinische Pharmakologie_729	Jilma Bernd
FA729A0166	A Phase 1 Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of ADX-097 in Healthy Participants (Placebo-Controlled, Double-Blind Single Ascending Dose and Multiple Dose) and in Patients With Either Bullous Pemphigoid (BP) or Discoid Lupus Erythematosus (DLE) (Open-Label, Single Dose and Multiple Ascending Dose)	Klinische Pharmakologie_729	Jilma Bernd
FA729A1045	VACCELERATE - European Corona Vaccine Trial Accelerator Platform	Klinische Pharmakologie_729	Zeitlinger Markus
FA729A1049	rhSOD in COVID-19	Klinische Pharmakologie_729	Zeitlinger Markus
FA729A1051	Investigation of Pharmacokinetics of Ceftazidime/Avibactam in Severely Burned Patients	Klinische Pharmakologie_729	Zeitlinger Markus

FA729A1052	Comparison of two different methods of saliva sampling for the detection of SARS-CoV-2 via an antigen rapid test against gold standard PCR	Klinische Pharmakologie_729	Zeitlinger Markus
FA729A1103	Effekte einer von Apothekern durchgeführten Medikationsanalyse auf Therapieadhärenz und andere Patienten-berichtete Parameter – eine randomisierte, kontrollierte, Patienten- und Beobachter-verblindete Studie in Patienten mit Polymedikation in Apotheken	Klinische Pharmakologie_729	Schörgenhofer Christian
FA729A1311	A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer	Klinische Pharmakologie_729	Schmidl Doreen
FA729A1701	A randomized, double-blind, active-controlled, cross-over study to assess the effect of the sugar substitute "ENSO 16" on glucose metabolism parameters in healthy subjects	Klinische Pharmakologie_729	Weisshaar Stefan
FA712A0306	Early Stage: Combination of Artemisinin with 5-ALA/heme biosynthesis modulators as novel therapy for brain tumors and other cancers	Krebsforschung_712	Berger Walter
FA712A0910	Daiichi HER3: Retrospektive Analyse von HER2 und HER3 Proteinexpression in Abhängigkeit zu neoadjuvanter AI- oder Chemotherapie in HER2-nicht überexprimierendem frühen Brustkrebs	Krebsforschung_712	Filipits Martin

FA712A1205	Exploratory study of health related physiological and biochemical parameters to identify simple, robust and relevant biomarkers for therapeutic interventions for PTSD patients	Krebsforschung_712	Holzmann Klaus
FA712A1401	Einfluss des Tumor Microenvironments auf Aggressivität und Therapieansprechen des Pleuramesothelioms	Krebsforschung_712	Grusch Michael
FA793A0905	Abwasserepidemiologische Untersuchungen von Kläranlagen an Schulstandorten/ Abwassermonitoring Schulstandorte	Labormedizin_793	Esterbauer Harald
FA793A2401	Identification of clinical, genetic and immunosuppressive factors predisposing to non-melanoma skin cancer (NMSC) in immunosuppressed organ transplant recipients compared to controls – a case-control study	Labormedizin_793	Sunder-Plaßmann Raute
FA793B0111	Influence of Chlorhexidine on C. albicans and C. glabrata upon long term exposure	Labormedizin_793	Willinger Birgit
FA793B0116	Testung von Cefiderocol bei multiresistenten gramnegativen Stäbchen	Labormedizin_793	Willinger Birgit
FA793B0309	Targeting mucosal biofilms in patients with gastrointestinal disorders	Labormedizin_793	Makristathis Athanasios
FA616A0903	Decrypting ufmylation through Chemical biology	Medizinische Biochemie_305	Karagöz Gülsün Elif
FA605A0309	SimulUS	Medizinische Physik und Biomedizinische Technik_340	Kollmann Christian
FA605A0602	3D Druck und Röntgen	Medizinische Physik und Biomedizinische Technik_340	Homolka Peter
FA605A0703	Development and application of implantable pulse generator for neuromuscular activation in mice	Medizinische Physik und Biomedizinische Technik_340	Lanmüller Hermann

FA605A1901	Additive Manufacturing for Medical Research	Medizinische Physik und Biomedizinische Technik_340	Moscato Francesco
FA605A1901	Additive Manufacturing for Medical Research	Medizinische Physik und Biomedizinische Technik_340	Moscato Francesco
FA605A1907	Optimized Hydrodynamic Flow Behaviour by Selective Surface Structured of Ceramic 3D Printed Rotodynamic Blood Pumps	Medizinische Physik und Biomedizinische Technik_340	Moscato Francesco
FA605A2205	Tomosynthesephantom	Medizinische Physik und Biomedizinische Technik_340	Figl Michael
FA605A2402	Magnetresonanzuntersuchungen aus Patientenperspektive; Praktika für Schüler:innen 2022	Medizinische Physik und Biomedizinische Technik_340	Frass Roberta
FA605A3001	Rb-PET-PRC: Positron range correction for cardiac Rubidium PET	Medizinische Physik und Biomedizinische Technik_340	Rausch Ivo
FA605A3002	MR visible polymer for medical imaging applications	Medizinische Physik und Biomedizinische Technik_340	Rausch Ivo
FA602A0201	Relevance of health outcome measures for vulnerable populations with rheumatic and musculoskeletal diseases	Medizinische Statistik, Informatik und Intelligente Systeme_303	Mosor Erika
FA631A0104	BY: Deep learning for improved nuclei segmentation and knowledge transfer methods in microscopic images	Medizinische Statistik, Informatik und Intelligente Systeme_303	Dorffner Georg
FA631A0501	EU H2021 A Coordination and Support Action to prepare UNCAN.eu platform	Medizinische Statistik, Informatik und Intelligente Systeme_303	Bock Christoph
FA632A0205	Statistical methods for time-to-event endpoints with non-proportional hazards in clinical trials pivotal for benefit risk decision making	Medizinische Statistik, Informatik und Intelligente Systeme_303	Posch Martin
FA660A0805	Implementation for the Action "European Health Data & Evidence Network"	Medizinische Statistik, Informatik und Intelligente Systeme_303	Duftschnid Georg
FA660A1105	Neuentwicklung eines Cardiac-Allocation-Scores (CAS)	Medizinische Statistik, Informatik und	Heinze Georg

		Intelligente Systeme_303	
FA660A1204	Optimal gender-specific treatment paths on healthcare multiplex networks	Medizinische Statistik, Informatik und Intelligente Systeme_303	Klimek Peter
UE63206001	Verein ASDI - Zertifizierung von Intensivstationen	Medizinische Statistik, Informatik und Intelligente Systeme_303	Graf Alexandra
FA742A0406	Osteokonduktive, antimikrobielle Beschichtungen für komplikationsfreie Polymer-3D-gedruckte Gesichts-Implantate	Mund-, Kiefer- und Gesichtschirurgie_742	Rusmüller Günter
FA736A0501	Rereseach in 5-ALA Fluorescence in Neurosurgery	Neurochirurgie_736	Widhalm Georg
FA736A0501	Rereseach in 5-ALA Fluorescence in Neurosurgery	Neurochirurgie_736	Widhalm Georg
FA736A0503	Hypericin-PVP in der photodynamischen Tumortherapie: ein neues Behandlungskonzept für Glioblastoma multiforme	Neurochirurgie_736	Widhalm Georg
FA736A0703	Die Rolle der Mitochondrien in der Neurodegeneration	Neurochirurgie_736	Rössler Karl
FA761A1135	The epidemiology and clinical characterisation of 5q-linked spinal muscular atrophy in Austria	Neurologie_761	Berger Thomas
FA761A1142	Open-label extension of the ARGX-113-1802 trial to investigate the long-term safety, tolerability and efficacy of Efgartigimod PH20 SC in patients with chronic inflammatory demyelinating Polyneuropathy (CIPD)	Neurologie_761	Berger Thomas
FA761A1143	Evaluation of a new therapeutic approach based on electrical stimulation to control cervical Dystonie (CD) symptoms	Neurologie_761	Berger Thomas
FA761A1144	Evaluation of the therapeutic effects of surface electrostimulation on patients suffering from cervical dystonia	Neurologie_761	Berger Thomas

FA761A1145	Evaluation of the therapeutic effects of surface elctrostimulation on patients suffering from Blepharospasm	Neurologie_761	Berger Thomas
FA761A1146	An integrated phase I/II, multicentre, double-blind, randomised, Dysport and placebo-controlled, dose escalation and dose finding study to evaluate the safety and efficacy of IPN10200 in the treatment of adult upper limb spasticity	Neurologie_761	Berger Thomas
FA761A1147	High-resolution 7 Tesla ultrahigh-field magnetic resonance imaging (SWI, MR venography) and optical coherence tomography in patients with relapsing and secondary progressive multiple sclerosis	Neurologie_761	Berger Thomas
FA761A1148	A phase III multicenter, randomized, double-blind, double-dummy study to evaluate safety and efficacy of ocrelizumab in comparison with Fingolimod in children and adolescents with relapsing-remitting Multiple Sclerosis	Neurologie_761	Berger Thomas
FA761A1149	A phase 2, randomized, double-blinded, placebo-controlled, parallel-group, multicenter trial to evaluate the safety and tolerability, efficacy, pharmacokinetics, pharmacodynamics and immunogenicity of 2 dose regimens of ARGX-117 in adults with multifocal motor neuropathy	Neurologie_761	Berger Thomas
FA761A1150	MuSic Moves - co-creating a music-supported exercise programme with people with multiple sclerosis	Neurologie_761	Berger Thomas

FA761A1151	A phase 3b, randomized, open-label, parallel-group study to evaluate different dosing regimens of intravenous Efgartigimod to maximize and maintain clinical benefit in patients with generalized Myasthenia Gravis	Neurologie_761	Berger Thomas
FA796A0112	Durchführungen von Leistungen im Rahmen der Umsetzung des Nationalen Aktionsplans für seltene Erkrankungen - Nationales Büro zur Umsetzung und Weiterentwicklung des NAP.se	Neurologie_761	Voigtlaender Till
FA796A0602	Deep gray matter iron and disease progression in multiple sclerosis	Neurologie_761	Hametner Simon
FA728A0605	COOL-AMI EU PIVOTAL TRIAL: A MULTICENTER, PROSPECTIVE, RANDOMIZED-CONTROLLED TRIAL TO ASSESS THE SAFETY AND EFFECTIVENESS OF COOLING AS AN ADJUNCTIVE THERAPY TO PERCUTANEOUS INTERVENTION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION	Notfallmedizin_728	Sterz Fritz
FA728A1202	„Patient*innen-Strom: Vernetzen.Verstehen.Versorgen“	Notfallmedizin_728	Niederdöckl Jan
FA737A0705	Eine randomisierte, Bewerter verblindete, dosisabhängige, proof-of-concept Studie zur Wirksamkeit, Sicherheit und Verträglichkeit von rhBMP6 (verabreicht in eigenem Blutkoagel, ergänzt mit synthetischer Keramik als kompressionsresistente Matrix) im Vergleich zu Knochenautotransplantat, nach einmaliger lokaler Verabreichung zusätzlich zu einer intramedullären Nagelfixierung zur Behandlung einer posttraumatischen distalen Tibiapseudarthrose.	Orthopädie und Unfallchirurgie_739	Chiari Catharina

FA737A1602	FFG Innovationsscheck PLUS IMD	Orthopädie und Unfallchirurgie_739	Rothbauer Mario
FA737A1902	Search for a common founder of the paricular p.His108ArgTTR variant	Orthopädie und Unfallchirurgie_739	Auer-Grumbach Michaela
FA737B0101	B1: Cartilage for Cartilage regeneration: Laser engraved decellularized cartilage as biomaterial for defect treatment	Orthopädie und Unfallchirurgie_739	Nürnbergger Sylvia
FA608A0324	IronSense	Pathobiochemie und Genetik_306	Scheiber-Mojdehkar Barbara
FA681A0206	Role of Matrix Metalloproteinase-12 in a mouse model of sarcoidosis	Pathobiochemie und Genetik_306	Weichhart Thomas
FA791A1025	A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis	Pathologie_791	Kain Renate
FA791A1149	A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)	Pathologie_791	Simonitsch-Klupp Ingrid
FA791A1423	A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations	Pathologie_791	Haitel Andrea

FA791A1637	Randomisierte, doppelblinde Phase-III-Studie zum Vergleich der Wirksamkeit und Sicherheit von Niraparib mit Placebo bei Teilnehmerinnen mit HER2-negativem BRCA-mutierten oder mit triple-negativem Mammakarzinom mit Molekularkrankheit basierend auf dem Vorliegen von zirkulierender Tumor-DNA nach einer definitiven Therapie (213831 ZEST)	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1638	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ATEZOLIZUMAB OR PLACEBO AND TRASTUZUMAB EMTANSINE FOR HER2-POSITIVE BREAST CANCER AT HIGH RISK OF RECURRENCE FOLLOWING PREOPERATIVE THERAPY	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1639	EMBER-3: A Randomized, Open-Label, Phase 3 Study of LY3484356 vs Investigator's Choice of Endocrine Therapy, in Patients with Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy	Pathologie_791	Bago-Horvath Zsuzsanna
FA791A1640	A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer	Pathologie_791	Bago-Horvath Zsuzsanna

FA791A2607	M18-868 - A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer	Pathologie_791	Geleff Silvana
FA791A2703	A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with ¹⁷⁷ Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET) – short title ‘COMPETE study’ Zentrum Prof. Haug	Pathologie_791	Mazal Peter
FA791A3407	Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)	Pathologie_791	Comperat Eva Maria
FA623A0220	INDUCTION OF HBV VIRUS NEUTRALIZING ANTIBODIES IN HEALTHY VACCINE NAIVE ADULTS AND NON-RESPONDERS AND IN PATIENTS CHRONICALLY INFECTED WITH HBV USING VVXX001	Pathophysiologie, Infektiologie und Immunologie_370	Wiedermann-Schmidt Ursula

FA623A0227	A Phase 3 Randomized, Double-blind, Active Comparator-controlled, LooT-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults 18 to 49 Years of Age	Pathophysiologie, Infektiologie und Immunologie_370	Wiedermann-Schmidt Ursula
FA623A0509	Prep213 Molecular characterization of <i>Cryptosporidium</i> spp. and <i>Giardia</i> spp. from diarrheic children, calves, and water sources in Bahir Dar city and peri-urban areas, northwest Ethiopia: A one health approach	Pathophysiologie, Infektiologie und Immunologie_370	Walochnik Julia
FA623A0510	Prep214 - Strengthening Genetic Biocontrol Capacities under Climate Change in Armenia	Pathophysiologie, Infektiologie und Immunologie_370	Walochnik Julia
FA623A0901	EU H2021 Immunomodulatory properties of <i>L. plantarum</i> extracellular vesicles in airway allergy	Pathophysiologie, Infektiologie und Immunologie_370	Schabussova Irma
FA624A0214	Scientific expert meeting NovoNordisk	Pathophysiologie, Infektiologie und Immunologie_370	Steinberger Peter
FA624A0304	KOOPERATIONSVERTRAG EZ4U	Pathophysiologie, Infektiologie und Immunologie_370	Ellmeier Wilfried
FA644A0507	An innovative strategy for the quantification and prediction of toxigenic and non-toxigenic <i>Vibrio cholerae</i> in environmental water resources	Pathophysiologie, Infektiologie und Immunologie_370	Kirschner Alexander
FA648A0313	Developing effective allergen-specific immunotherapy	Pathophysiologie, Infektiologie und Immunologie_370	Valenta Rudolf
FA648A0315	Monitoring of PreS-specific immune responses in the course of the clinical study: Evaluate induction of HBV Virus Neutralizing Antibodies Using VVX001 (ClinicalTrials.gov Identifier: NCT03625934)	Pathophysiologie, Infektiologie und Immunologie_370	Valenta Rudolf

FA648A0808	Analysis of allergen-induced degranulation of basophil cells	Pathophysiologie, Infektiologie und Immunologie_370	Breiteneder Heimo
FA648A1020	BY: Deep learning for improved nuclei Segmentation and knowledge Transfer methods in microscopic images	Pathophysiologie, Infektiologie und Immunologie_370	Ellinger Isabella
FA648A1711	The impact of allergen-immunotherapy (AIT) formulations on immunogenicity and efficacy of AIT in a murine model	Pathophysiologie, Infektiologie und Immunologie_370	Untersmayr-Elsenhuber Eva
FA648A2003	PCR-Ressourcen	Pathophysiologie, Infektiologie und Immunologie_370	Schepelmann Martin
UE64806002	Schimmelpilzallergie in Österreich	Pathophysiologie, Infektiologie und Immunologie_370	Jensen-Jarolim Erika
UE72606002	Similarities and differences between responses to epidural versus whole body non-invasive neuromodulation with focus to pain treatment	Physikalische Medizin, Rehabilitation und Arbeitsmedizin_726	Crevenna Richard
FA625A1102	Themis - Onkologische Therapieoptionen	Physiologie und Pharmakologie_350	Schabbauer Gernot
FA625A1102	Themis - Onkologische Therapieoptionen	Physiologie und Pharmakologie_350	Schabbauer Gernot
FA763B0443	An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment resistant Depression. Safety and Sustainance of Esketamine Treatment Response With Repeated Doses at Intervals Determined by Symptom Severity (SUSTAIN 2)	Psychiatrie und Psychotherapie_763	Wancata Johannes
FA763C0801	VOICE – Patient Involvement in Individuals with lived experience of Clinical High Risk for Psychosis	Psychiatrie und Psychotherapie_763	Hinterbuchinger Barbara
FA646A0303	EU H2021 - ISIDORE	Public Health_380	Kutalek Ruth
FA646A1201	ACE Casino	Public Health_380	Fischer Gabriele
FA646A1202	ASW Wetten	Public Health_380	Fischer Gabriele

FA647A0118	EU Knowledge for improving indoor AIR quality and HEALTH	Public Health_380	Moshammer Hanns
FA647A0801	New Options for Resilient Measures for human health and well-being in the construction industry under climate change in Austria	Public Health_380	Haluza Daniela
FA669A0110	Investigation of diagnostic and treatment pathways and comorbidity profiles of prostate and colorectal cancer patients focusing on health economic aspects in AT	Public Health_380	Simon Judit
UE64606004	Nahda University of Beni Suef (NUB)	Public Health_380	Rieder Anita
FA771B0415	Integrated Decision Support - Breast Cancer	Radiologie und Nuklearmedizin_771	Helbich Thomas
FA771B0880	Multi-center, double-blind, randomized, placebo-controlled, phase IIa trial to evaluate spesolimab (BI 655130) efficacy in patients with fibrostenotic Crohn's Disease	Radiologie und Nuklearmedizin_771	Herold Christian
FA771B0881	A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ELA026 Following Intravenous and/or Subcutaneous Administration of Single and Multiple Doses in Healthy Adults	Radiologie und Nuklearmedizin_771	Herold Christian
FA771B0882	Dual Source CT SOMATOM Drive	Radiologie und Nuklearmedizin_771	Herold Christian
FA771B1701	"A Randomized, Double blind, Placebo controlled, Ascending Multiple dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Romosozumab in Children and Adolescents with Osteogenesis Imperfecta"	Radiologie und Nuklearmedizin_771	Herold Christian

FA771D0319	Longterm follow up and mortality rate of patients of the Freeway Stent Study	Radiologie und Nuklearmedizin_771	Loewe Christian
FA771D0518	CA209-650: Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer	Radiologie und Nuklearmedizin_771	Wolf Florian
FA771D0528	Eine retrospektive PMCF-Studie zur Bewertung der klinischen Sicherheit und Wirksamkeit des S.M.A.R.T. Flex Stent Iliac, S.M.A.R.T. Flex SFA/PP, S.M.A.R.T. Control Nitinol Stent, S.M.A.R.T. Nitinol Stent, PALMAZ Blue 0.18 Peripherer Stent auf Slalom, PALMAZ Genesis .035 Peripherer Stent auf Opta Pro, SABER OTW PTA Katheter, SABERX PTA Dilatationskatheter und PowerFlex Pro PTA Katheter für die endovaskulären Interventionen in den ilio-femoropoplitealen Gefäßen.	Radiologie und Nuklearmedizin_771	Wolf Florian
FA771E0215	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Crohn's Disease	Radiologie und Nuklearmedizin_771	Kainberger Franz
FA771E0315	Placebo-controlled Trial in subjects at Ultra-high Risk for Psychosis with Ómega-3 fatty acidS in Europe	Radiologie und Nuklearmedizin_771	Langs Georg
FA771E0707	A randomized, placebo-controlled, subject and investigator blinded study investigating the safety, tolerability and preliminary efficacy of 8-week treatment with intra-articular LRX712 to regenerate articular cartilage in	Radiologie und Nuklearmedizin_771	Trattnig Siegfried

	patients with mild/moderate knee osteoarthritis		
FA771E0708	A randomized, placebo-controlled, subject and investigator blinded study investigating the safety, tolerability and preliminary efficacy of 8-week treatment with intra-articular LRX712 to regenerate articular cartilage in patients with mild/moderate knee osteoarthritis	Radiologie und Nuklearmedizin_771	Trattning Siegfried
FA771E1004	A Phase 1/2, Multicenter, Open-label, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in Pediatric Patients with Relapsed/Refractory Solid Tumors Harboring a Mutation in KIT or PDGFRA	Radiologie und Nuklearmedizin_771	Furtner-Srajner Julia
FA771E1501	“ A PHASE IIIb, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SUBCUTANEOUS EMICIZUMAB IN PATIENTS FROM BIRTH TO 12 MONTHS OF AGE WITH HEMOPHILIA A WITHOUT INHIBITORS ”	Radiologie und Nuklearmedizin_771	Nöbauer-Huhmann Iris-Melanie
FA771G0243	Herstellung von Radiometallmarkierten Arzneimitteln mittels automatisierter Systeme und deren Qualitätskontrolle	Radiologie und Nuklearmedizin_771	Hacker Marcus

FA771G0257	Radiochemistry development and optimization of an Iodide-131 labelled isoSGMIB-Nanobody for preclinical applications	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA771G0265	A multicentre Surveillance Study to Evaluate the Long-term Safety in Participants who Have Been Previously Treated with 177Lu-IPN01072 in an Ipsen-sponsored Clinical Study.	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA771G0266	Development of a "Chelate to Release" Labeling Platform for Synthesis of high molar activity Radiopharmaceuticals	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA771G0267	Automatisierte Radiosynthesen innovativer PET-Tracer mittels FASTlab	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA771G0268	Validierung der automatisierten Synthese von PET-Tracern (z.B. alpha-Methyl-4 (18F)FDG)	Radiologie und Nuklearmedizin_771	Hacker Marcus
FA774A0204	"Tailored Axillary Surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS). A multicenter randomized open labeled phase III trial" ("Studie")	Radioonkologie_774	Kauer-Dorner Daniela
FA774A0502	Technische Funktionalität und Design vom ETD Prototyp	Radioonkologie_774	Lechner Wolfgang
FA774A0503	Korrelation von Oberflächendaten mit X-Ray Daten (Phantombehandlung)	Radioonkologie_774	Lechner Wolfgang
FW774A0101	FWF Pre-clinical Ion Beam Research - DFH 13-B	Radioonkologie_774	Georg Dietmar

FA774A0702	A multi-centre, open-label, single-arm, dose-finding phase I/II study to evaluate safety, tolerability, dosing schedule, and preliminary efficacy of carrier-added 4-L-[131I]iodo-phenylalanine (131I-IPA), administered as single or repetitive injections in patients with recurrent glioblastoma multiforme (GBM), concomitantly to 2nd line external radiation therapy (XRT) - IPAX-1Study	Strahlentherapie_774	Dieckmann Ute
FA731C0212	Pathomechanisms of vascular remodelling - reverse remodelling strategies	Thoraxchirurgie_733	Hötzenecker Konrad
FA731T0501	Prophylaktische Anwendung der Extrakorporalen Photopherese nach Lungentransplantation - eine prospektive randomisierte Studie	Thoraxchirurgie_733	Jaksch Peter
FA733A0201	Evaluating the addition of hemodiafiltration to ex-vivo lung perfusion – impact on the regeneration of marginal donor lungs: a prospective randomised pilot trial	Thoraxchirurgie_733	Benazzo Alberto
FA670A0103	"Vergleich der Genauigkeit digitaler versus konventioneller Implantat-getragener Kronenversorgungen: eine klinische Studie"	Universitätszahnklinik_670	Schedle Andreas
FA670A0108	Erstellen von Kriterien zur Beurteilung der Qualität von Kompositmaterialien und der Langlebigkeit von Kompositfüllungen	Universitätszahnklinik_670	Schedle Andreas

FA670B0204	Eine randomisierte klinische Prüfung zur vergleichenden Untersuchung einer bioresorbierbaren Magnesium NOVAMag® Membran mit Kollagen Jason® Membran bei Patienten die eine gesteuerte Knochenregeneration benötigen	Universitätszahnklinik_670	Zechner Werner
FA743A0111	A phase III, multicenter, randomized study of Atezolizumab (Anti-PD-L1 Antibody) in combination with Enzalutamide versus Enzalutamide alone in patients with metastatic castration-resistant prostate cancer after failure of an Androgen synthesis inhibitor and failure of, ineligibility for, or refusal of a taxane regimen	Urologie_743	Kramer Gero
FA743A0112	APhase III, open label, randomized study to assess the efficacy and safety of Olaparib (Lymparza TM) versus Enzalutamide or Abiraterone Acetate in men with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have homologous recombination repair gene mutations (PROfound)	Urologie_743	Kramer Gero
FA743A0220	Eine multinationale, randomisierte, doppelblinde, placebokontrollierte Phase-III-Studie zur Wirksamkeit und Sicherheit von ODM-201 bei männlichen Hochrisikopatienten mit nicht metastasiertem, kastrationsresistentem Prostatakrebs	Urologie_743	Shariat Shahrokh

FA743A0230	Beurteilung des Xpert Blasenkrebsmonitor-Tests im Vergleich zur Zystoskopie für die Nachbeobachtung von Patienten mit Vorgeschichte von geringem bis mittlerem Risiko eines nicht-muskelinvasiven Blasenkrebses (NMIBC): eine prospektive internationale multizentrische Beobachtungsstudie	Urologie_743	Shariat Shahrokh
FA743A0240	Characterization of the PARP Inhibitor Talazoparib as Novel Therapeutic Option in Advanced Bladder Cancer	Urologie_743	Shariat Shahrokh
FA743A0266	Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)" (MK-3475-365-Site number 2702)	Urologie_743	Shariat Shahrokh
FA690A0505	Testung von TTV DNA nach Nierentransplantation	Virologie_307	Puchhammer Elisabeth

Markus Müller

Rektor